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Abstract
Background—Growing recognition that active surveillance (AS) is a reasonable management 
option for many men diagnosed with localized prostate cancer led us to describe patients’ 
conceptualizations of AS and reasons for their treatment decisions.
Methods—Men were patients of a multidisciplinary prostate cancer clinic at a large tertiary 
cancer center where patients are routinely briefed on treatment options, including AS. We 
conducted a thematic analysis of interviews with 15 men who had chosen AS and 15 men who 
received radiation or surgery.
Results—Men who chose AS described it as an organized process with a rigorous and reassuring 
protocol of periodic testing, with potential for subsequent and timely decision making about 
treatment. AS was seen as prolonging their current good health and function with treatment still 
possible later. Rationales for choosing AS included trusting their physician's monitoring, “buying 
time” without experiencing adverse effects of treatment, waiting for better treatments, and seeing 
their cancer as very low risk. Men recognized the need to justify their choice to others because it 
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seemed contrary to the impulse to immediately treat cancer. Descriptions of AS by men who chose 
surgery or radiation were less specific about the testing regimen. Getting rid of the cancer and 
having a cure were paramount for them.
Conclusions—Men fully informed of their treatment options for localized prostate cancer have 
a comprehensive understanding of the purpose of AS. Slowing the decision-making process may 
enhance the acceptability of AS.
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Introduction
For men diagnosed with localized prostate cancer (PCa), observation may be a viable 
management option [1-6]. Clinical guidelines from the National Comprehensive Cancer 
Network [5] and the American Urological Association [6] include the option of observation 
for men with localized PCa that is deemed low risk on the basis of the tumor's characteristics 
and the patient's life expectancy. Yet among men with low-risk disease, less than a fifth 
select it over immediate treatment [7, 8].
Observation has been described as “active surveillance” (AS), “watchful waiting,” or 
“expectant management,” but historically these terms have often been used without specific 
definitions [3]. This lack of clarity complicates evaluation of the scientific literature on 
observation [9]. Recently, the National Institutes of Health issued a consensus statement 
defining AS “as a disease management strategy that delays curative treatment until it is 
warranted based on defined indicators of disease progression” (p. 4) [3]. In contrast, with 
watchful waiting, curative treatment is not the goal and treatment is initiated when the 
patient becomes symptomatic.
Not a great deal is known about the choice of AS among men with PCa. Only a few surveys 
and qualitative studies have been used to collect patients’ views on AS and their reasons for 
choosing it over treatment. A qualitative study of 25 Canadian men who had selected AS 
found that they perceived that their cancer was not an immediate threat to their health or life 
and wanted to avoid the side effects of treatment [10]. The physician's recommendation for 
observation was also an important influence. The importance of support from physicians, as 
well as from family members, as a factor in selecting AS has been noted by other 
researchers as well [11].
With the current study, we sought a richer understanding of the views on AS of patients 
diagnosed with localized PCa. This project used qualitative methods to explore patients’ 
conceptualizations of AS and treatment decision making. The results will be used to inform 
the development of patient education and decision support tools to assist men and their 
health care providers who may find these value-based decisions difficult.
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Subjects for this study were recruited from the Multidisciplinary Prostate Cancer Clinic 
(MPCC) at The University of Texas MD Anderson Cancer Center. On the basis of a 
thorough assessment of a patient's tumor characteristics, potential longevity, and other 
medical and psychosocial concerns, the MPCC educates the patient about his cancer and 
management choices. Patients are seen by a urologist and radiation oncologist in the same 
clinic, one then the other usually just a few minutes apart. The team then confers and makes 
a joint recommendation about treatment options, including AS. Patients who select AS are 
referred to a protocol for monitoring.
Eligible patients were men diagnosed with prostate cancer defined as cancer that had not 
spread beyond the prostate gland at the time of diagnosis. Men who were re-staged higher at 
the time of treatment were not eligible to participate. All respondents were English speaking.
Two groups of patients were targeted for recruitment. First, the AS patients must have 
chosen AS and be 6 to 18 months from the decision to enter the AS protocol. This time 
frame was selected to allow patients to have had several months of experience with this 
protocol, including returning to the MPCC for surveillance, but few would have already 
transitioned to active treatment because of disease progression. These men were further 
selected to ensure a mix of patients younger than and older than 65 years of age.
The second group were men with localized disease who chose to be treated surgically or 
with radiation. Surgery and radiation patients were selected to be 6 to 18 months following 
treatment (the date of surgery or completion of the course of radiation). In this time window, 
the acute recovery period would have passed and most patients would have achieved 
continence. Because surgery patients tend to be younger than radiation therapy patients, we 
sampled to produce a mix of men under and over 60 years of age for surgery and under and 
over 70 years of age for radiation therapy.
The eligibility of each patient who agreed to participate was confirmed via medical record 
review. Of the 36 men who were contacted, 30 agreed to participate (15 AS patients and 15 
treated patients). The study was described to them as involving a telephone-based interview 
about their treatment decisions in order to help with the development of educational 
materials for men facing similar decisions. The project was reviewed and approved for use 
of human subjects by the Institutional Review Board of the MD Anderson Cancer Center 
and the Committee for the Protection of Human Subjects, The University of Texas Health 
Science Center at Houston.
Interview Procedures
Audiorecorded telephone interviews were conducted by male interviewers between May and 
August 2011. The interview was structured around the following topics: treatment options 
discussed and considered, a description of AS using the patient's own words, how the 
treatment decision was made, recommendations made by the health care team, and the role 
of others (e.g., a partner) in decision making. Specific questions were asked about the 
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importance of treatment-related side effects (e.g., impotence, urinary and bowel 
incontinence) in the treatment decision. A payment of $50 was made to participants at the 
end of the interview.
Data Analysis
The purpose of our analysis was to identify themes across all 30 interviews and within the 
two patient cohorts. In identifying the themes, we began with the topic areas in the 
interviews (e.g., involvement of a partner in the decision) and augmented them with themes 
emerging from the respondents’ interviews (e.g., the physician's evaluation as a factor in the 
decision process).
Once the audiotapes were transcribed, we performed the initial coding of the transcripts, 
familiarized ourselves with the interviews, and then identified more detailed themes. We 
worked with two general-purpose computer programs to code the original transcripts and to 
generate reports of retrieved coded sections. That is, we abstracted chunks of text from the 
numbered transcript files prepared in Microsoft Word and copied them to Microsoft Access, 
a general database program for assignment of descriptors (e.g., AS vs. T [for immediate 
treatment]) and thematic codes. This approach provided the functionality of code searching 
and retrieval found in specialized qualitative data analysis software but without the expense 
or effort of using a special-purpose computer program.
Transcripts were assigned to individual coders who were members of the research team and 
experienced in qualitative methods for the initial selection of chunks of text into the 
database. We then worked from major chunks to identify subthemes. In our analysis 
meetings, two persons presented their coding results, accepted additional input from other 
analysts, and reconciled coding disagreements. Quotes provided below are identified by the 
patient group (AS vs. T) and a patient number.
Results
Patient Characteristics
Men in the AS group were on average 62.6 ± 7.6 years old (range, 49–72 years), and men in 
the treatment group were on average 58.6 ± 6.9 years old (range, 45–70 years). Most men 
had at least some college education, all but two classified themselves as white, and three 
quarters were married (Table 1). More than twice as many men who had been treated than 
men in the AS group reported having a relative who had had PCa (47% versus 20%).
Definition of AS
All respondents were asked about their understanding of AS. We also read a definition to the 
treated men and asked about circumstances where they think a man with localized prostate 
cancer should select AS.
Theme 1: AS Is an Organized, Supportive Process—AS men gave a consistent 
description of AS: meet with their physician twice a year, have prostate-specific antigen 
(PSA) tests, undergo an annual biopsy, and at least yearly discuss with their physician the 
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decision to be on AS. This set of activities accurately covers what is involved in AS for PCa 
within this treatment environment.
Among AS men, monitoring was viewed as an organized process that is supportive should a 
change occur: “I really like the fact that [the hospital] was kind of putting me in a program.” 
(AS10) There was satisfaction with regular monitoring, which was seen as a system to check 
whether the tumor was getting out of hand. One man summarized that he was:
“...comfortable with the idea that they were going to watch me closely enough and 
with enough skill that if this began to be more aggressive or turn into something 
[else], that they would recognize it and then it would be time to get involved in 
[active treatment].” (AS5)
The results of tests and biopsies provide information that allows the medical team and 
patient to determine when implementing curative treatment would be appropriate. AS is not 
a matter of going it alone; the patient is part of a team. The men described their trust in their 
treatment teams.
This group compared AS with watchful waiting. For example,
“Active surveillance is essentially waiting on having surgery or other types of 
treatments for prostate cancer. It's a watchful program, where you wait and see 
whether the cancer is growing or how much it is growing.... The thing I like about 
the active surveillance is... it's not active waiting. The active part is the emphasis.” 
(AS14)
In contrast, the treated men described AS in its general contours and as a less active process: 
“Basically you sit back and watch and wait and periodically do testing to see the progression 
of the disease.” (T27) Treated men were less specific about time intervals and the tests 
involved, did not distinguish between watchful waiting and AS, did not see AS as involving 
an organized program or being part of an ongoing relationship with the treatment team.
Treated men described the principal goal of treatment as cure (“taking care of it” or “getting 
rid of it”). They valued the fact that they had made a definitive choice to deal with the 
cancer. For them, the key issue was getting rid of the cancer.
Finally, some treated men erroneously associated AS with any sort of monitoring such as 
post-treatment monitoring with PSA tests to assess for recurrence: “Let's get rid of it and do 
the watchful waiting afterwards.” (T27) Others applied the term AS for some other disease 
altogether. For example, a man who had had melanoma referred to his regular skin checks as 
AS.
Theme 2: AS Prolongs Current Good Health—The decision for AS was seen by men 
not as a final decision but likely the first of a sequence of decisions. AS provides an interval 
in which to continue enjoying current health and function without undergoing treatment or 
risking the side effects of treatment. One man described AS as fitting with his 5-year plan: 
the program would evaluate him each year, but he had slated himself a major time of 
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reflection after 5 years. The idea behind AS is to “buy some time from having to make a 
difficult decision that involved potential risk.” (AS11)
Factors Associated with Treatment Decision
One advantage of this study is that both treated and AS men had undergone a similar 
multistage process to reach an initial treatment decision. In several cases, men described 
being diagnosed by a community-based urologist, but they may also have had consultations 
with other urologists, radiation oncologists, or other specialists before being seen at the 
cancer center. Some had been dissatisfied with the treatment options they had been offered 
and skeptical about the motivations of the diagnosing clinician. At MD Anderson, patients 
had undergone another biopsy and participated in multiple consultations at the MPCC. Here, 
we organized the analysis of factors in men's treatment decisions around three topics: a) how 
men described their condition, b) pros and cons of the treatment option, and c) physician 
support.
Theme 3: Viewing Their Cancer as Low Risk and Having Time to Decide About 
Treatment—Men in the AS cohort described the tumor as being small and could give a 
detailed account of biopsy results. For example, one man recalled,
“My particular diagnosis appeared to be a very small cancer risk.... Of the cores 
that were taken in my initial biopsy, only one core returned with a cancer sample 
and it was less than 1 mm. The other cores were negative. And my second biopsy, 
all the cores were negative.” (AS12)
These men also referred to the slow growing nature of their cancer, but there was greater 
emphasis on how it was only “a little” cancer.
AS men believed they still had time to make a decision about active treatment. In light of the 
slow growth of their cancer and small tumor size, they concluded that immediate treatment 
was unnecessary. One man summarized the situation as, “It's not like you just had a heart 
attack.” (AS17)
The disadvantage of AS is that the cancer could, despite its small size, be aggressive. AS 
men said this concern was less important because regular monitoring would be sufficient to 
detect any changes and that effective treatment could be introduced then. Several men in the 
AS group thought that postponing treatment might allow sufficient time for technological 
advances when they were ready to receive treatment.
Thirteen of the 15 treated men did not characterize the size or nature of their condition. 
Their descriptions of biopsy results were general rather than detailed: “Once you have a 
biopsy, deal with it.” (T20) Treated men did not refer to slow-growing tumors.
Theme 4: Avoidance of Side Effects of Treatment—The principal reason for 
selecting AS was to avoid the side effects of treatment, particularly those affecting sexual 
function. This is one participant's interpretation:
“I believe that the risk of those side effects right now is greater than the risk of my 
dying of prostate cancer. And implied in that statement is the idea that suffering 
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those side effects is equivalent to dying. That's not a bad description of the way I 
feel about it.” (AS5)
Theme 5: Importance of Physician Recommendation about AS—AS men had 
conducted substantial independent research regarding the decision for AS or immediate 
treatment but valued physician input as well. According to one patient, “I asked [the 
physician] what he would do [in my situation]. And he said active surveillance.” (AS3) AS 
men also described their confidence in the doctors running the AS program.
Other Themes
Theme 6: Justifying the Decision to Others—AS men recognized that their decision 
was counter to expected norms for people with cancer, and at times they felt the need to 
justify their decision to other people. They commented that the decision was often more 
difficult for their spouses than for themselves. One AS man reported that once he convinced 
his children that he was not suicidal, they generally agreed with his decision. Another man 
mentioned that not only was he not worried about having PCa, but he would almost forget 
he had PCa and needed to remind himself to mention it on medical history forms.
Theme 7: Desire for Immediate Cure—Among treated men, the principal reason for 
selecting active treatment for PCa (i.e., surgery or radiotherapy) was described variously as 
protecting one's life, wanting a cure, or wanting to remove the cancer from the body. Treated 
patients had understood the risk of adverse consequences of treatment before they had 
decided to follow their “gut reaction” to “cut it out.”
Treated men reported that their physicians communicated about the level of risk for side 
effects. However, treated patients placed a higher priority on actively treating the disease. 
One participant stated: “I was overwhelmingly wanting to get rid of the cancer, so that was 
really driving me. Not necessarily being able to still perform sexually was not going to 
outweigh getting rid of the cancer out of my body.” (T22)
Treated men discussed their choice of treatment in relation to other possible active 
treatments and rarely in relation to AS. Some men expressed preferences for specific 
treatment features, mentioning that the outcome with one type of radiation was as good as 
that with surgery or that there are fewer sexual side effects with radiation than with surgery. 
A patient who had selected brachytherapy described the radiation seeds as going “right 
where they are needed,” (T2) a claim for precision. Patients also mentioned drawbacks or 
advantages in relation to the treatment delivery and recovery time: one man rejected surgery 
because he thought the recovery time would be too long. Some of the radiation options 
would have required treatment far from home for a lengthy period, which was highly 
undesirable for some men. Finally, men talked about advantages of particular physicians or 
forms of treatment.
Discussion
In this qualitative study, men with localized PCa who had chosen AS over immediate 
treatment gave highly quantified and detailed descriptions of their condition. Telling their 
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stories in this way may reinforce the decision to be monitored and show that they made a 
sensible choice. These data are also a crucial part of surveillance, so they are relevant until a 
decision to receive treatment is made. In contrast, treated men did not give such detailed 
descriptions; they might have had these facts at their fingertips at the time of the decision to 
undergo treatment and then forgotten the details, as they were no longer pertinent.
Adapting a broader model [12], Penson [13] developed a systematic-heuristic model of 
decision making around the acceptance of and adherence to AS for localized PCa. The 
systematic process involves gathering information, analyzing thoughts and feelings about 
the information, and integrating the information to form preferences and make a decision; it 
is a deliberative, time-consuming, and cognitively difficult process. In contrast, heuristic 
processing is far less taxing and requires less information; decisions are based on 
preconceived expectations, schemas, stereotypes, and commonsense “rules of thumb” 
learned and modified through interactions with others. A heuristic strategy relies on only a 
subset of information and short-cut rules to make decisions quickly [12]. According to the 
model, using heuristic short cuts to selectively interpret information can lead to bias in 
systematic processing. Penson argues that factors related to the initial acceptance of and 
long-term adherence to AS can be explained by this model [13].
Penson's model provides an organizing framework for the themes we identified. In our 
study, AS men demonstrated systematic processing both in their conceptualization of AS 
and their decision-making about PCa management, and they revealed in-depth 
understanding of the periodic testing required by the AS protocol. They also found that this 
structured monitoring provided reassurance. Patients who chose immediate treatment 
offered far less detail in their conceptualizations of AS, seeing it as indistinguishable from 
watchful waiting.
The concept of time was important both for information seeking and making the 
management decision. For AS, slowing the decision making process allowed men to gather 
more information about their options and consider the opinions of others. They were able to 
counter the prevailing heuristics that cancer must be treated immediately and aggressively 
and that delaying treatment means risking disease progression and death [14]. AS men 
demonstrated understanding that their current health status could be prolonged, their cancer 
would be carefully monitored, and they could decide on curative treatment later if the cancer 
progressed. For men who chose immediate treatment, extending the decision-making time 
was seen as a threat to longevity.
Understanding the level of risk associated with localized PCa was a key factor in men's 
decisions to select AS. Other studies have observed that AS patients often believe in the 
indolent nature of their cancer and that immediate treatment is unnecessary [13, 15-17]. 
These observations have clear implications for the design of interventions that educate men 
about a spectrum of risks and include messages that not all cases of localized PCa are the 
same.
A strength of this study is that the AS cohort and the treated cohort were drawn from the 
same clinical population, with each person having gone through a multistage process of 
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consultation and information seeking. In addition, the qualitative analysis of perceptions and 
treatment decisions permitted the study participants to discuss factors of concern to them 
rather than being limited to closed-ended questions.
There are limitations to this study. This study was largely limited to white, non-Hispanic 
men treated at a large cancer center. Views of active surveillance may be very different for 
men treated in the community, including those from disadvantaged groups [18]. While there 
may be an increase in the use of multidisciplinary models for PCa treatment in the United 
States, current PCa programs may be difficult to replicate in community settings. The 
MPCC gives men the opportunity to consider alternatives, but the aggressiveness of the 
cancer, the presence of comorbidities, and other considerations can restrict options. Some of 
the treated men reported that AS was not recommended to them.
Slowing the decision making process may be conducive to more systematic decision-making 
by men with localized PCa. Most men learn their diagnosis from the urologist who 
conducted the biopsy [19]. Studies vary in the extent to which men report seeing other 
specialists after diagnosis [19]. How can the consideration of AS be made more compatible 
with current medical practice? Patient decision aids may play an important role in slowing 
the decision-making process, giving men and others involved in the decision time to 
deliberate about the options, and encouraging men to question the options they are offered 
[20]. Patient decision aids educate patients about their options and allow them to compare 
attributes, and potential harms and benefits, deliberate about tradeoffs, begin to construct 
their preferences for the options, and make an informed, values-based decision with their 
health care provider [21]. The findings from this study will inform the messages to be 
communicated in the design of such interventions.
In addition to providing patients with high quality evidence, patient decision aids can 
encourage patients to actively pursue treatment options appropriate to their situation and 
cancer, provide them with the language with which to have meaningful conversations with 
their health care providers about treatment and observation, and encourage adherence to AS 
protocols for patients who decide on observation.
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Table 1
Sociodemographic Characteristics of Men with Localized Prostate Cancer
Characteristic Active surveillance (n=15) Immediate treatment 
*
 (n=15)
No. % No. %
Education
    High school graduate or less 0 0.0 4 26.7
    Some college or college graduate 8 53.3 6 40.0
    Postgraduate 7 46.7 4 26.7
    Not stated 0 0.0 1 6.7
White, non-Hispanic 15 100.0 13 86.7
Annual income
    Under $50,000 1 6.7 1 6.7
    $50,000–$99,999 5 29.4 9 60.0
    $100,000 and above 7 46.7 4 26.7
    Not stated 2 13.3 1 6.7
Currently married 11 73.3 11 73.3
Family member with prostate cancer 3 20.0 7 46.7
*
Brachytherapy (n = 6 men), proton therapy (n = 1), robotic prostatectomy (n = 5), or open prostatectomy (n = 3).
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